Ampersand Biomedicines
Daniel Blom currently serves as Chief Scientific Officer and Chief Technology Officer at Ampersand Biomedicines since January 2022. Prior to this role, Daniel held the position of Senior Vice President Drug Discovery and Development and Vice President Biologics Drug Development at Cygnal Therapeutics from July 2019 to November 2021. Daniel's experience at GSK spanned from November 2013 to June 2019 as Director of Biology for both Discovery Partnerships with Academia and Virtual Proof of Concept. At Merck & Co, Inc, Daniel worked from November 2004 to October 2013 as Director of Biologics Strategy focusing on Cardiovascular Diseases. Earlier in the academic field, Daniel was a postdoctoral fellow at both Harvard Medical School from 2001 to 2004 and the University of Amsterdam from 1999 to 2001. Daniel earned a PhD in Biochemistry and an MSc in Chemistry, both from the University of Amsterdam, completing the PhD in 1999 after obtaining the MSc in 1993.
This person is not in any offices
Ampersand Biomedicines
Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.